Loading filters...
Publications per Year (410 total)
1
·
1
·
1
·
1
2000
1
·
1
·
1
·
1
·
4
2005
2
·
2
·
2
·
1
·
6
·
2
·
2
·
4
·
2
2015
14
·
20
·
16
·
25
·
26
2020
45
·
32
·
39
·
50
·
65
2025
43
·
Loaded
Click to load
50 / 410 papers loaded(scroll for more)
202643 papers
ADCadvanced2026
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
Zhu Y et al. Ann Oncol. 2026
Immunotherapyadvanced2026
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.
Wu J et al. Cancer Res. 2026
ADCAll Stages2026
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer.
Wang Y et al. Cancer Cell. 2026
Generaladvanced2026
Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma.
Wang B et al. Urol Oncol. 2026
ADCearly2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C et al. N Engl J Med. 2026
ADCAll Stages2026
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy.
Uysal D et al. Urol Oncol. 2026
ADCadvanced2026
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
Jindal T et al. Urol Oncol. 2026
Immunotherapyearly2026
ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
Dyrskjøt L et al. Ann Oncol. 2026
FGFR alteredAll Stages2026
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.
Daneshmand S et al. Eur Urol. 2026
Generalearly2026
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
Necchi A et al. Lancet Oncol. 2026
Generaladvanced2026
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.
Moinard-Butot F et al. Urol Oncol. 2026
Immunotherapyearly2026
Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
Schmid SC et al. Eur Urol Oncol. 2026
Immunotherapyearly2026
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Tateo V et al. Eur Urol. 2026
Immunotherapyearly2026
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis.
Petrelli F et al. Urol Oncol. 2026
ADCadvanced2026
Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
Miederer M et al. BJU Int. 2026
ImmunotherapyAll Stages2026
The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.
Roels J et al. Cancer Res. 2026
ImmunotherapyAll Stages2026
Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.
Yajima S et al. Urol Oncol. 2026
NMIBCAll Stages2026
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.
Myers AA et al. Eur Urol. 2026
Immunotherapyearly2026
Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer.
Molina-Cerrillo J et al. Eur Urol Oncol. 2026
ImmunotherapyAll Stages2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
Mellema JJ et al. Nat Med. 2026
NMIBCAll Stages2026
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
McElree IM et al. BJU Int. 2026
Generaladvanced2026
Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.
Litt HK et al. Urol Oncol. 2026
Generaladvanced2026
ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.
Xing Z et al. Br J Cancer. 2026
Immunotherapyadvanced2026
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.
Aggen DH et al. Clin Cancer Res. 2026
Generaladvanced2026
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.
Bedke J et al. ESMO Open. 2026
Immunotherapyadvanced2026
Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trial.
Li Z et al. Clin Cancer Res. 2026
Immunotherapyearly2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
Thibault C et al. J Clin Oncol. 2026
Immunotherapyearly2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.
Guercio BJ et al. Clin Cancer Res. 2026
GeneralAll Stages2026
Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
Ghoreifi A et al. Urol Oncol. 2026
Immunotherapyadvanced2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
Gebrael G et al. Bladder Cancer. 2026
Generalearly2026
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Galsky MD et al. Ann Oncol. 2026
FGFR alteredadvanced2026
Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.
Pant S et al. Clin Cancer Res. 2026
FGFR alteredadvanced2026
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study.
Loriot Y et al. J Clin Oncol. 2026
Immunotherapyearly2026
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.
Mirkheshti N et al. Clin Cancer Res. 2026
Generaladvanced2026
Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study.
Ishimoto K et al. Urol Oncol. 2026
Generaladvanced2026
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
Rosenberg JE et al. ESMO Open. 2026
Immunotherapyearly2026
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
Elias R et al. J Urol. 2026
GeneralAll Stages2026
Venous invasion in upper tract urothelial carcinoma: Diagnostic features and oncologic outcomes.
Brönimann S et al. Urol Oncol. 2026
NMIBCAll Stages2026
Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience.
Moyer JA et al. Urol Oncol. 2026
Immunotherapyearly2026
Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.
Develtere D et al. Eur J Cancer. 2026
Immunotherapyearly2026
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.
Cathomas R et al. J Clin Oncol. 2026
ImmunotherapyAll Stages2026
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).
Roupret M et al. Ann Oncol. 2026
Immunotherapyearly2026
AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.
Necchi A et al. Eur Urol Oncol. 2026
20257 papers
Immunotherapyadvanced2025
Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan.
Yasuoka S et al. Urol Oncol. 2025
Generalearly2025
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates.
Yanagisawa T et al. Bladder Cancer. 2025
ADCAll Stages2025
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines.
van der Heijden AG et al. Eur Urol. 2025
ADCadvanced2025
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Jindal T et al. Eur Urol Oncol. 2025
ADCAll Stages2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
Powles T et al. Ann Oncol. 2025
Immunotherapyadvanced2025
Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.
Tomita Y et al. Urol Oncol. 2025
ImmunotherapyAll Stages2025
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Tateo V et al. Clin Cancer Res. 2025